Circumference Reduction Clinical Trial
Official title:
Evaluation of Safety and Efficacy of Using Venus Freeze™ (MP)2 V2 System for Wrinkles Rhytides and Cellulite Treatment - a Pilot Study
NCT number | NCT01234259 |
Other study ID # | VN-WR- 01 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | December 2010 |
Est. completion date | September 2014 |
Verified date | April 2020 |
Source | Venus Concept |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Skin aging is a multifactorial process involving the 3 layers of the skin: Epidermis, dermis
and hypodermis.
Radio-frequency (RF) devices have been used for many years for a variety of surgical
applications. The energy delivery systems of these established monopolar devices used a
'conductive coupling' delivery system in which energy is concentrated at the periphery of the
electrode.
Venus Concept has developed the Venus Freeze (MP)2 V2 system for wrinkles, rhytides and
temporary cellulite and circumference reduction treatments. While treating wrinkles rhytides
and cellulite, the treatments creates enough thermal effect to induce collagen remodeling
with no ablative thermal damage in the epidermis or dermis.
Status | Completed |
Enrollment | 60 |
Est. completion date | September 2014 |
Est. primary completion date | September 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 30 Years and older |
Eligibility |
Inclusion Criteria: - Healthy males and females age 30 and up - Subjects with Fitzpatrick 4 to 9 degrees of elastosis - Subject able to comprehend and give informed consent for participation in this study - Subject must commit to all treatments and follow-up visits - Subject must sign the Informed Consent Form Exclusion Criteria: - Subjects with implanted pacemakers, arrhythmias or any other severe known heart disorder - Subjects with any implantable metal device in the treatment area - Subjects on any medication that would affect the characteristic of the skin (medical or hormonal), such as "Accutane", within the past 6 months or photosensitizing medications - Subjects that have had any other invasive or non invasive method of skin therapy or hair removal performed in the past 9 months (in the treated area) Subjects who are scheduled or planned for any other invasive or non invasive method of skin therapy or hair removal in the treated area at the period of the study - Subjects who have any form of malignant skin cancer on the treatment area - Subjects with history of keloid formations or hypertrophic scarring - Pregnant or lactating Subjects - Subjects with Epilepsy or severe migraines - Subjects with permanent makeup/ tattoo/ body piercing (in the treated area) - Subjects with any Infection / abscess / dermatitis/ pains in treatment target area. - Subjects who suffer from autoimmune disorders or diabetes - Subjects with clotting disorders - Subjects are suffering from psychiatric disorders and treated with psychiatric medications. - Subject is suffering extreme general weakness. - Subject objects to the study protocol - Concurrent participation in any other clinical study - Physician objection |
Country | Name | City | State |
---|---|---|---|
Israel | Sourasky medical Centre | Tel-Aviv |
Lead Sponsor | Collaborator |
---|---|
Venus Concept |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the efficacy of the Venus system for wrinkles rhytides and temporary cellulite and circumference reduction treatment. Efficacy evaluation will include RF, Magnetic Pulse Field and vacuum technology. | Efficacy will be established by skin improvement as a result of the treatment by validated scales. Results will be compared to control group results. The pre - and post-treatment photographs will be compared and assessed by three independent dermatologists. | 5 months | |
Secondary | To evaluate the safety of the Venus Freeze (MP)2 V2 system for wrinkles, rhytides, temporary cellulite and circumference reduction. Safety evaluation will include RF, Magnetic Pulse Field and vacuum technology. | Safety parameters will include adverse events (signs of pain; edema; burn; localized infection; skin pigmentation & texture alterations) occurring as a direct result of the treatment and complaints up to last follow up visit. | 5 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02109107 -
Study of Low Level Laser Light Therapy on Circumference Reduction
|
N/A | |
Terminated |
NCT01026441 -
Clinical Study to Evaluate the Safety and Efficacy of the Vela100
|
Phase 4 | |
Completed |
NCT05674292 -
An Evaluation of the Effect of the Erchonia Corporation Violet Zerona® Z6 for Body Contouring
|
N/A | |
Recruiting |
NCT02956720 -
UltraShape Power in Combination With U-sculpt-n Transducer
|
N/A | |
Terminated |
NCT02591056 -
Study of the Combined Effect of Low Level Laser Therapy and Manual Lymph Drainage on Reducing Body Circumference
|
N/A | |
Completed |
NCT03430245 -
VelaShape III & UltraShape Power for Thigh Circumference Reduction
|
N/A |